We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Nmn8.5
NMN Research
Likely helpsModerate safety
27 peer-reviewed studies
What the evidence says
Likely helps
NMN appears to help in 5 of 6 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2020–2026 with a typical study size of 48 participants.
Based on 27 studies · 4 meta-analyses · 19 RCTs · 3,349 total participants
Confidence
High
What the studies found
5helped1unclear· 21 more without graded effect data
24 studies in the last 5 years · Latest meta-analysis: 2026
20202026
1Gait speedMeta-Analysisn=412 · medium study2025
NMN has positive efficacy in enhancing muscle function, reducing insulin resistance and lowering aminotransferase levels in middle-aged and elderly individuals.
Wang JP et al. · Current pharmaceutical biotechnology (2025)
Noticeable benefit
← WorseNo effectBetter →
Likely real
Based on changes in gait speed (SMD: 0.34 m/s, 95%CI [0.03, 0.66] p = 0.033), NMN had significant effects on muscle mass.
Moreover, NMN had a better effect on ALT (SMD: -0.29 IU/L, 95%CI [-0.55, -0.03] p = 0.028).
NMN has positive efficacy in enhancing muscle function, reducing insulin resistance and lowering aminotransferase levels in middle-aged and elderly individuals.
Based on the small number of RCTs involving mainly relatively healthy adults, short-term supplementation of NMN of 250-2000 mg/d did not show significantly positive impacts on glucose control and lipid profile.
3NAD+ therapy benefit/risk analysisSystematic ReviewCited 69×n=1,545 · large study2020
Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence.
Braidy N et al. · Experimental gerontology (2020)
Potential risks in raising NAD+ levels in various clinical disorders using NAD+ precursors include the accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence.
Therefore, NAD+ metabolism represents a promising target and further studies are needed to recapitulate the preclinical benefits in human clinical trials.Crown
Results of preclinical and clinical studies confirm the potential benefits of NAD+ precursors for the treatment of AD.
Alghamdi M et al. · Journal of Alzheimer's disease : JAD (2024)
Results of preclinical and clinical studies confirm the potential benefits of NAD+ precursors for the treatment of AD.
However, further clinical studies are required to confirm the increasingly important value of NAD+ precursors as effective pharmacological interventions in the clinic.
6Blood pressureMeta-Analysisn=349 · medium study2026
However, the potential of NMN as a viable candidate for early-stage blood pressure management requires confirmation through long-term, large-scale, high-quality RCTs in future clinical studies.
Zhang M et al. · Nutrients (2026)
Noticeable benefit
← WorseNo effectBetter →
Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).
In contrast, the reduction in resting SBP was not statistically significant.
Notably, subgroup analyses revealed that NMN supplementation resulted in a significant reduction in SBP specifically among participants aged 60 years and older (WMD: -3.94 mmHg; 95% CI: -7.06 to -0.82).
This mechanistic RCT provides direct evidence that NMN enhances skeletal muscle NAD+ and improves insulin sensitivity, strengthening the translational case for NMN as a metabolic health intervention.
Statistical analysis was performed using the Per Protocol analysis with significant level set at p = 0.05.
Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001).
Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01), with longest walking distances measured in the 600 mg and 900 mg groups.
95-chair stand test performanceRCTCited 53×n=108 · medium study2022
These findings suggest the potential of NMN in preventing loss of physical performance and improving fatigue in older adults.
Kim M et al. · Nutrients (2022)
Noticeable benefit
← WorseNo effectBetter →
Significant interactions were observed between 5-STS and drowsiness. 5-STS of all groups on post-intervention and drowsiness of the NMN_PM and Placebo_PM groups on mid- and post-intervention showed significant improvement compared with those in pre-intervention.
The NMN_PM group demonstrated the largest effect size for 5-STS (d = 0.72) and drowsiness (d = 0.64).
Overall, NMN intake in the afternoon effectively improved lower limb function and reduced drowsiness in older adults.
14Mitochondrial content in exercised muscleRCTn=11 · very small study2026
NMN supplementation, while inhibiting inflammatory signaling in exercised human skeletal muscle, may also suppress mitochondrial replenishment from phagocytes to repairing myofibers.
Yang DL et al. · Journal of the International Society of Sports Nutrition (2026)
Huge benefit
← WorseNo effectBetter →
BFR-exercise increased the mitochondrial content in exercised muscle by 171% after 24 h of recovery.
NMN supplementation, while inhibiting inflammatory signaling in exercised human skeletal muscle, may also suppress mitochondrial replenishment from phagocytes to repairing myofibers.
Ultimately, we propose a gut-dependent model for the modes of action of the three NAD+ precursors with NR and NMN elevating circulatory NAD+ via the Preiss-Handler pathway, while rapidly absorbed Nam acutely affects NAD+ levels via the salvage pathway.
Overall, these results indicate a dual effect of NR and NMN and their microbially produced metabolite NA: a sustained increase in systemic NAD+ levels and a potent modulator of gut health.
We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flus...
Li X et al. · Free radical biology & medicine (2023)
We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN).
In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky.
In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions.
17circulating NAD levels and metabolomeRCTCited 39×2023
MIB-626 1 000 mg once-daily or twice-daily regimens were safe and associated with substantial dose-related increases in blood NAD levels and its metabolome.
Pencina KM et al. · The journals of gerontology. Series A, Biological sciences and medical sciences (2023)
MIB-626 1 000 mg once-daily or twice-daily regimens were safe and associated with substantial dose-related increases in blood NAD levels and its metabolome.
These foundational data that were obtained using a pharmaceutical-grade βNMN, standardized sample collection, and validated liquid chromatography-tandem mass spectrometry assays, should facilitate design of efficacy trials in disease conditions.
MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure.
Pencina KM et al. · The Journal of clinical endocrinology and metabolism (2023)
MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure.
These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.
19Grip strength and walking speedRCTCited 24×n=14 · very small study2023
In older male patients with diabetes and impaired physical performance, NMN supplementation for 24 weeks was safe, but did not improve grip strength and walking speed.
Akasaka H et al. · Geriatrics & gerontology international (2023)
No clear effect
← WorseNo effectBetter →
In older male patients with diabetes and impaired physical performance, NMN supplementation for 24 weeks was safe, but did not improve grip strength and walking speed.